Trinity Biotech plc
TRIB

$13.64 M
Marketcap
$1.20
Share price
Country
$0.04
Change (1 day)
$3.55
Year High
$1.05
Year Low

Trinity Biotech plc acquires, develops, manufactures, and markets medical diagnostic products for the clinical laboratory and point-of-care (POC) segments of the diagnostic market in the Americas, Africa, Asia, and Europe. The company offers clinical laboratory products, including diagnostic tests and instrumentation, which detect infectious diseases, such as lyme disease; sexually transmitted diseases consisting syphilis and herpes; SARS-CoV-2; and epstein barr, measles, mumps, toxoplasmosis, cytomegalovirus, rubella, varicella and other viral pathogens, as well as products for the in-vitro diagnostic testing for haemoglobin A1c used in the monitoring and diagnosis of diabetes, and identifying those who are at a risk of developing diabetes. It also develops, manufactures, and sells products in the immunofluorescence assay, enzyme-linked immunosorbent, western blot, and line immunoassay formats; and provides reagent products, such as ACE, bile acids, lactate, oxalate, and glucose-6-phosphate dehydrogenase for diagnosis of liver and kidney diseases, as well as haemolytic anaemia. In addition, the company sells raw materials to the life sciences industry and research institutes. It serves public health authorities, non-governmental organisations, and clinical and reference laboratories through its direct sales force, as well as through a network of independent distributors and strategic partners. Trinity Biotech plc was incorporated in 1992 and is headquartered in Bray, Ireland.

marketcap

Revenue of Trinity Biotech plc (TRIB)

Revenue in 2023 (TTM): $56.83 M

According to Trinity Biotech plc's latest financial reports the company's current revenue (TTM) is $56.83 M. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.

Revenue history of Trinity Biotech plc

Annual Revenue

Year Revenue Gross Profit Ebitda Income Before Tax Net Income
2023 $56.83 M $18.5 M $-13,484,000 $-36,927,000 $-24,018,000
2022 $74.78 M $22.05 M $-8,277,000 $-41,194,000 $-41,002,000
2021 $92.97 M $38.08 M $15.9 M $751 K $875 K
2020 $101.98 M $48.58 M $22.18 M $-6,633,000 $-6,013,000
2019 $90.44 M $38.12 M $5.77 M $821 K $-4,066,000
2018 $97.04 M $41.45 M $7.42 M $3.03 M $2.39 M
2017 $99.14 M $41.89 M $6.29 M $1.6 M $-40,270,000
2016 $99.61 M $43.09 M $9.92 M $5.19 M $-100,626,000
2015 $100.2 M $46.25 M $26.36 M $22.88 M $21.8 M
2014 $104.87 M $50.35 M $18.14 M $18.07 M $17.21 M
2013 $91.22 M $45.91 M $19.17 M $19.1 M $10.34 M
2012 $82.51 M $42.25 M $19.45 M $19.36 M $17.34 M
2011 $77.95 M $40.13 M $18.21 M $18.2 M $15.59 M
2010 $89.64 M $43.95 M $15.38 M $61.36 M $60.42 M
2009 $125.91 M $57.02 M $14.11 M $12.92 M $11.82 M
2008 $140.14 M $62.49 M $-71,469,000 $-81,670,000 $-77,778,000
2007 $143.62 M $55.25 M $-22,026,000 $-32,063,000 $-35,372,000
2006 $118.67 M $50.78 M $8.09 M $452 K $3.28 M
2005 $98.56 M $47.18 M $10.7 M $5.95 M $5.28 M
2004 $79.94 M $40.26 M $10.13 M $5.22 M $5.17 M
2003 $65.68 M $32.8 M $12.96 M $7.98 M $5.8 M
2002 $51.98 M $25.61 M $10.27 M $5.51 M $5.01 M
2001 $37.06 M $18.92 M $8.7 M $1.66 M $1.45 M
2000 $29.74 M $16.3 M $9.78 M $4.95 M $4.82 M
1999 $26.1 M $13.09 M $6.27 M $5.57 M $4.92 M
1998 $23.2 M $8.8 M $3.7 M $ $2.6 M
1997 $16.8 M $5.9 M $1.6 M $1.4 M $1.2 M
1996 $7.2 M $1.7 M $-300,000 $-900,000 $-900,000
1995 $9.9 M $2.2 M $-2,600,000 $-800,000 $-800,000
1994 $5.2 M $800 K $-1,600,000 $-3,600,000 $-3,300,000
1993 $2.4 M $200 K $-3,800,000 $-4,400,000 $-3,400,000